| Indicators | Browse All

Cocrystal Pharma, Inc. (COCP)

Healthcare | Biotechnology | Bothell, United States | NasdaqCM
1.10 USD -0.04 (-3.509%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 1.10

Short-term:★★☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 5:41 a.m. EDT

The immediate outlook is bearish due to a relentless multi-year price collapse and severe operational distress. The stock has endured nine consecutive years of negative annual returns, with the entire nine-year window showing a catastrophic -99% cumulative loss, signaling a deep structural deterioration rather than a temporary setback. Fundamentally, the company is bleeding cash aggressively, reporting negative operating margins of -30%, negative free cash flow, and negative returns on both assets and equity. The balance sheet is fragile, with debt-to-equity exceeding 128x and no cash reserves to speak of relative to obligations. While the recent price action shows a minor bounce off the lows, this is insufficient to overcome the overwhelming evidence of a failing business model. Furthermore, there is no dividend income to offset these risks, making this a high-risk speculative vehicle with no margin of safety.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.126844
AutoARIMA0.131945
AutoTheta0.132516
AutoETS0.132576

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 34%
H-stat 3.47
Ljung-Box p 0.000
Jarque-Bera p 0.276
Excess Kurtosis 0.20
Attribute Value
Sector Healthcare
Debt to Equity Ratio 128.448
Revenue per Share 0.025
Market Cap 21,189,520
Forward P/E -1.90
Beta 1.43
Website https://www.cocrystalpharma.com

Info Dump

Attribute Value
52 Week Change -0.24000001
Address1 19,805 North Creek Parkway
All Time High 1,440.0
All Time Low 0.76
Ask 1.45
Ask Size 2
Average Analyst Rating 1.0 - Strong Buy
Average Daily Volume10 Day 63,970
Average Daily Volume3 Month 71,650
Average Volume 71,650
Average Volume10Days 63,970
Beta 1.427
Bid 0.8496
Bid Size 2
Book Value 0.076
City Bothell
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.1
Current Ratio 1.237
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 1.18
Day Low 1.1
Debt To Equity 128.448
Display Name Cocrystal Pharma
Dividend Date 1,516,752,000
Earnings Timestamp End 1,755,084,600
Earnings Timestamp Start 1,755,084,600
Ebitda -10,060,000
Ebitda Margins 0.0
Enterprise To Ebitda -2.024
Enterprise To Revenue 61.702
Enterprise Value 20,361,520
Eps Current Year -0.69
Eps Forward -0.58
Eps Trailing Twelve Months -0.75
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.016
Fifty Day Average Change 0.08399999
Fifty Day Average Change Percent 0.082677156
Fifty Two Week Change Percent -24.0
Fifty Two Week High 2.67
Fifty Two Week High Change -1.57
Fifty Two Week High Change Percent -0.58801496
Fifty Two Week Low 0.76
Fifty Two Week Low Change 0.34000003
Fifty Two Week Low Change Percent 0.44736847
Fifty Two Week Range 0.76 - 2.67
Financial Currency USD
First Trade Date Milliseconds 1,329,921,000,000
Float Shares 11,852,454
Forward Eps -0.58
Forward P E -1.8965518
Free Cashflow -4,318,750
Full Exchange Name NasdaqCM
Full Time Employees 10
Fullday Change -0.04
Fullday Change Percent -3.50877
Fullday Price 1.1
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -5,756,000
Has Pre Post Market Data 1
Held Percent Insiders 0.65712
Held Percent Institutions 0.057740003
Implied Shares Outstanding 19,263,200
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,665,446,400
Last Split Factor 1:12
Long Business Summary Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
Long Name Cocrystal Pharma, Inc.
Market us_market
Market Cap 21,189,520
Market State CLOSED
Max Age 86,400
Message Board Id finmb_49062639
Most Recent Quarter 1,782,777,600
Net Income To Common -9,938,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 22,152,680
Number Of Analyst Opinions 2
Open 1.18
Operating Cashflow -7,954,000
Operating Margins -30.32381
Payout Ratio 0.0
Phone 877 262 7123
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 1.1
Post Market Time 1,787,947,804
Previous Close 1.14
Price Eps Current Year -1.594203
Price Hint 4
Price To Book 14.473685
Price To Sales Trailing12 Months 64.21067
Profit Margins 0.0
Quick Ratio 1.11
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.0
Region US
Regular Market Change -0.04
Regular Market Change Percent -3.50877
Regular Market Day High 1.18
Regular Market Day Low 1.1
Regular Market Day Range 1.1 - 1.18
Regular Market Open 1.18
Regular Market Previous Close 1.14
Regular Market Price 1.1
Regular Market Time 1,787,947,200
Regular Market Volume 28,740
Return On Assets -0.96072996
Return On Equity -3.11683
Revenue Per Share 0.025
Sand P52 Week Change 0.20504117
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 19,263,200
Shares Percent Shares Out 0.016
Shares Short 307,605
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 395,023
Short Name Cocrystal Pharma, Inc.
Short Percent Of Float 0.0194
Short Ratio 4.75
Source Interval 15
State WA
Symbol COCP
Target High Price 10.0
Target Low Price 8.0
Target Mean Price 9.0
Target Median Price 9.0
Total Cash 2,169,000
Total Cash Per Share 0.113
Total Debt 1,341,000
Total Revenue 330,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.75
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.0859
Two Hundred Day Average Change 0.014100075
Two Hundred Day Average Change Percent 0.01298469
Type Disp Equity
Volume 28,740
Website https://www.cocrystalpharma.com
Zip 98,011